Geron Corporation (GERN) 2.75 $GERN Mylan (MYL)
Post# of 273257
Posted On: 09/03/2016 1:16:52 PM
Geron Corporation (GERN) 2.75 $GERN
Mylan (MYL) Gets Positive Copaxone USPTO Ruling Yet Again
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:07AM CDT
Mylan (MYL) reported that the U.S. Patent and Trademark Office has invalidated the third patent covering Copaxone (40 mg/mL) via inter partes review proceeding.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32)
Amgen Gets FDA Approval for Label Expansion of Blincyto
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 7:45AM CDT
Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion for its leukemia immunotherapy Blincyto.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Allergan, Adamas Agree to Settle Namzaric Patent Litigation
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:23AM CDT
Allergan (AGN) along with Adamas entered into a settlement agreement with Amneal to resolve the patent infringement litigation related to Namzaric.
AGN: 235.96 (-1.80), ADMS: 14.76 (-0.31), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05)
Pfizer's Lung Cancer Drug Xalkori Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:42AM CDT
Pfizer, Inc. (PFE) announced that its lung cancer drug Xalkori has been approved for an additional indication by the European Commission (EC).
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), PFE: 34.77 (+0.09)
ARIAD Finishes Rolling NDA for Lung Cancer Drug Brigatinib
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:24AM CDT
ARIAD Pharmaceuticals (ARIA) completed the rolling submission of the new drug application for brigatinib, to the FDA.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), PFE: 34.77 (+0.09), ARIA: 10.12 (-0.07)
Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:04AM CDT
Alexion Pharmaceuticals' (ALXN) ALXN1007 received orphan drug designation in the EU for the treatment of graft-versus-host disease.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ALXN: 123.67 (-1.96), ANIK: 47.89 (-0.05)
Inovio Stock Up as Second Zika Virus Vaccine Study Begins
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:07AM CDT
Inovio Pharmaceuticals' (INO) shares were up after the company started a second study evaluating its preventive Zika vaccine, GLS-5700, in Puerto Rico.
INO: 9.08 (-0.06), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), XON: 25.33 (+0.04)
Mylan (MYL) Obtains Favorable USPTO Ruling for Copaxone
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:29AM CDT
Mylan (MYL) announced that the U.S. Patent and Trademark Office has invalidated two of Teva Copaxone 40 mg patents in an inter partes review.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32)
Momenta Pharmaceuticals (MNTA) Jumps: Stock Up 11.3%
Tuhin Roy - Zacks Investment Research - Thu Aug 25, 7:25AM CDT
Momenta Pharmaceuticals Inc. (MNTA) moved big last session, as its shares jumped a little over 11% on the day.
GERN: 2.75 (+0.02), MNTA: 12.30 (+0.15)
Clovis (CLVS) Stock Up on FDA Priority Review for Rucaparib
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 5:48AM CDT
The FDA will respond on the approval status of rucaparib by Feb 23, 2017.
CLVS: 23.40 (-0.19), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02)
Gilead (GILD) Truvada Gets EU Approval for Label Expansion
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:02AM CDT
Gilead Sciences (GILD) once-daily Truvada gains EU approval for reducing the risk of sexually acquired HIV-1 infection.
GILD: 76.89 (-0.53), GERN: 2.75 (+0.02), CORT: 5.31 (-0.04), ANIK: 47.89 (-0.05)
Regeneron Stock Up on BARDA Deal for MERS Antibodies
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:48AM CDT
Regeneron Pharmaceuticals (REGN) has signed up with BARDA for the development of treatments targeting MERS viru
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 9.6%
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 7:25AM CDT
Alder Biopharmaceuticals Inc. (ALDR) moved big last session, as its shares jumped almost 10% on the day.
ALDR: 31.52 (-1.02), GERN: 2.75 (+0.02)
Sanofi Diabetes Combination Drug FDA Action Date Extended
Arpita Dutt - Zacks Investment Research - Mon Aug 22, 8:29AM CDT
Sanofi (SNY) submitted updated information on the pen delivery device as part of its NDA for the fixed-ratio combination.
CBM: 43.27 (+0.10), GERN: 2.75 (+0.02), SNY: 39.18 (+0.77)
Pfizer's (PFE) Pain Drug Troxyca ER Receives FDA Approval
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:45AM CDT
Pfizer (PFE) gained FDA approval for Troxyca ER with abuse-deterrent properties for the management of pain.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), PFE: 34.77 (+0.09), TEVA: 51.22 (+0.32)
Horizon (HZNP) Rayos Receives USPTO Notice of Allowance
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:22AM CDT
Horizon Pharma (HZNP) announced that it has received a notice of allowance from the U.S. Patent and Trademark Office with claims covering Rayos.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), HZNP: 17.84 (-0.78), CORT: 5.31 (-0.04)
Aclaris (ACRS) Common Warts Candidate Positive in Phase II
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:18AM CDT
Aclaris (ACRS) announced positive results from a phase II study (WART-201) on A-101 Topical solution for the treatment of common warts.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ACRS: 20.86 (+0.18), ANIK: 47.89 (-0.05)
Portola (PTLA) Stock Down on CRL for AndexXa BLA in U.S.
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:16AM CDT
Portola (PTLA) received a Complete Response Letter for AndexXa (andexanet alfa) in the U.S.
PTLA: 21.03 (+0.17), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05)
Intercept (ICPT) Ocaliva Phase III POISE Data Published
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:12AM CDT
Intercept Pharmaceuticals (ICPT) announced the publication of phase III POISE study data on Ocaliva for the treatment primary biliary cholangitis.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ICPT: 150.74 (+3.92)
Anthera Pharmaceuticals (ANTH) Jumps: Stock Rises 7.9%
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 7:25AM CDT
Anthera Pharmaceuticals, Inc. (ANTH) moved big last session, as its shares jumped almost 8% on the day.
ANTH: 2.93 (+0.02), GERN: 2.75 (+0.02)
Mylan (MYL) Gets Positive Copaxone USPTO Ruling Yet Again
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:07AM CDT
Mylan (MYL) reported that the U.S. Patent and Trademark Office has invalidated the third patent covering Copaxone (40 mg/mL) via inter partes review proceeding.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32)
Amgen Gets FDA Approval for Label Expansion of Blincyto
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 7:45AM CDT
Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion for its leukemia immunotherapy Blincyto.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Allergan, Adamas Agree to Settle Namzaric Patent Litigation
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:23AM CDT
Allergan (AGN) along with Adamas entered into a settlement agreement with Amneal to resolve the patent infringement litigation related to Namzaric.
AGN: 235.96 (-1.80), ADMS: 14.76 (-0.31), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05)
Pfizer's Lung Cancer Drug Xalkori Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:42AM CDT
Pfizer, Inc. (PFE) announced that its lung cancer drug Xalkori has been approved for an additional indication by the European Commission (EC).
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), PFE: 34.77 (+0.09)
ARIAD Finishes Rolling NDA for Lung Cancer Drug Brigatinib
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:24AM CDT
ARIAD Pharmaceuticals (ARIA) completed the rolling submission of the new drug application for brigatinib, to the FDA.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), PFE: 34.77 (+0.09), ARIA: 10.12 (-0.07)
Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:04AM CDT
Alexion Pharmaceuticals' (ALXN) ALXN1007 received orphan drug designation in the EU for the treatment of graft-versus-host disease.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ALXN: 123.67 (-1.96), ANIK: 47.89 (-0.05)
Inovio Stock Up as Second Zika Virus Vaccine Study Begins
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:07AM CDT
Inovio Pharmaceuticals' (INO) shares were up after the company started a second study evaluating its preventive Zika vaccine, GLS-5700, in Puerto Rico.
INO: 9.08 (-0.06), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), XON: 25.33 (+0.04)
Mylan (MYL) Obtains Favorable USPTO Ruling for Copaxone
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:29AM CDT
Mylan (MYL) announced that the U.S. Patent and Trademark Office has invalidated two of Teva Copaxone 40 mg patents in an inter partes review.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32)
Momenta Pharmaceuticals (MNTA) Jumps: Stock Up 11.3%
Tuhin Roy - Zacks Investment Research - Thu Aug 25, 7:25AM CDT
Momenta Pharmaceuticals Inc. (MNTA) moved big last session, as its shares jumped a little over 11% on the day.
GERN: 2.75 (+0.02), MNTA: 12.30 (+0.15)
Clovis (CLVS) Stock Up on FDA Priority Review for Rucaparib
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 5:48AM CDT
The FDA will respond on the approval status of rucaparib by Feb 23, 2017.
CLVS: 23.40 (-0.19), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02)
Gilead (GILD) Truvada Gets EU Approval for Label Expansion
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:02AM CDT
Gilead Sciences (GILD) once-daily Truvada gains EU approval for reducing the risk of sexually acquired HIV-1 infection.
GILD: 76.89 (-0.53), GERN: 2.75 (+0.02), CORT: 5.31 (-0.04), ANIK: 47.89 (-0.05)
Regeneron Stock Up on BARDA Deal for MERS Antibodies
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:48AM CDT
Regeneron Pharmaceuticals (REGN) has signed up with BARDA for the development of treatments targeting MERS viru
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 9.6%
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 7:25AM CDT
Alder Biopharmaceuticals Inc. (ALDR) moved big last session, as its shares jumped almost 10% on the day.
ALDR: 31.52 (-1.02), GERN: 2.75 (+0.02)
Sanofi Diabetes Combination Drug FDA Action Date Extended
Arpita Dutt - Zacks Investment Research - Mon Aug 22, 8:29AM CDT
Sanofi (SNY) submitted updated information on the pen delivery device as part of its NDA for the fixed-ratio combination.
CBM: 43.27 (+0.10), GERN: 2.75 (+0.02), SNY: 39.18 (+0.77)
Pfizer's (PFE) Pain Drug Troxyca ER Receives FDA Approval
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 6:45AM CDT
Pfizer (PFE) gained FDA approval for Troxyca ER with abuse-deterrent properties for the management of pain.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), PFE: 34.77 (+0.09), TEVA: 51.22 (+0.32)
Horizon (HZNP) Rayos Receives USPTO Notice of Allowance
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:22AM CDT
Horizon Pharma (HZNP) announced that it has received a notice of allowance from the U.S. Patent and Trademark Office with claims covering Rayos.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), HZNP: 17.84 (-0.78), CORT: 5.31 (-0.04)
Aclaris (ACRS) Common Warts Candidate Positive in Phase II
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:18AM CDT
Aclaris (ACRS) announced positive results from a phase II study (WART-201) on A-101 Topical solution for the treatment of common warts.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ACRS: 20.86 (+0.18), ANIK: 47.89 (-0.05)
Portola (PTLA) Stock Down on CRL for AndexXa BLA in U.S.
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:16AM CDT
Portola (PTLA) received a Complete Response Letter for AndexXa (andexanet alfa) in the U.S.
PTLA: 21.03 (+0.17), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05)
Intercept (ICPT) Ocaliva Phase III POISE Data Published
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:12AM CDT
Intercept Pharmaceuticals (ICPT) announced the publication of phase III POISE study data on Ocaliva for the treatment primary biliary cholangitis.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ICPT: 150.74 (+3.92)
Anthera Pharmaceuticals (ANTH) Jumps: Stock Rises 7.9%
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 7:25AM CDT
Anthera Pharmaceuticals, Inc. (ANTH) moved big last session, as its shares jumped almost 8% on the day.
ANTH: 2.93 (+0.02), GERN: 2.75 (+0.02)
(0)
(0)Scroll down for more posts ▼